AIM
GHDX

Acrospire Investment Management’s Genomic Health, Inc. GHDX Stock Holding History

Acrospire Investment Management’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,744
Closed -$57K – 1846
2017
Q2 		$57K Sell
1,744
-1,100
-39% -$34.8K 0.05% 734
2017
Q1 		$90K Sell
2,844
-4,300
-60% -$127K 0.07% 393
2016
Q4 		$210K Buy
7,144
+5,300
+287% +$162K 0.09% 329
2016
Q3 		$53K Buy
1,844
+200
+12% +$5.57K 0.04% 1029
2016
Q2 		$43K Buy
+1,644
New +$43.7K 0.03% 1177

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Acrospire Investment Management's GHDX Position: Q3 2017 in Review

Acrospire Investment Management sold out of Genomic Health, Inc. (GHDX) in Q3 2017, closing a stake of 1,744 shares — an estimated $57K sold.

Acrospire Investment Management first reported a position in GHDX in Q2 2016 and held it in 5 quarters. The position peaked at $210K in Q4 2016. 134 funds tracked by Wall St. Rank hold GHDX as of Q3 2017.

  • Acrospire Investment Management reported no remaining Genomic Health, Inc. position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1,744 Genomic Health, Inc. shares in Q3 2017, an estimated $57K.
  • Acrospire Investment Management first reported a position in Genomic Health, Inc. in Q2 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Genomic Health, Inc. position peaked at $210K in Q4 2016.
  • 134 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.